Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2013

01-07-2013 | Research

Galectin-3 Accelerates the Progression of Oral Tongue Squamous Cell Carcinoma via a Wnt/β-catenin-Dependent Pathway

Authors: Li-Ping Wang, Shu-Wei Chen, Shi-Min Zhuang, Huan Li, Ming Song

Published in: Pathology & Oncology Research | Issue 3/2013

Login to get access

Abstract

The purpose of this study was to elucidate the clinicopathological significance and mechanism of action of galectin-3 in oral tongue squamous cell carcinoma (OTSCC). Here, the expression of galectin-3 was quantified in OTSCC (n = 68) and paired OTSCC and normal surrounding tissues (n = 10) using immunohistochemical staining. Tca8113 OTSCC cells were transfected with a plasmid expressing galectin-3 cDNA or siRNA against galectin-3. Cell proliferation, migration and invasion were measured using the MTT assay, Matrigel-coated Transwell migration assay and wound healing assay. The effect of galectin-3 on the Wnt/β-catenin signaling pathway and epithelial mesenchymal transition (EMT) were investigated using a plasmid expressing the Wnt antagonist dickkopf 1 (DKK1) and Western blotting. Galectin-3 was expressed at significantly higher levels in OTSCC than the normal adjacent tissues; galectin-3 expression correlated strongly with pathological stage, pathological grade and lymph node invasion in OTSCC. Overexpression of galectin-3 promoted Tca8113 cell proliferation, migration and invasion, upregulated Wnt protein expression, activated β-catenin and induced the EMT; knockdown of galectin-3 had the opposite effects. Co-transfection of Tca8113 cells overexpressing galectin-3 with the Wnt antagonist DKK1 reduced the ability of galectin-3 to increase cell proliferation, migration and invasion, reduced upregulation of Wnt, inhibited β-catenin activation and abrogated the EMT, demonstrating that the Wnt/β-catenin signaling pathway mediated the effects of galectin-3. Galectin-3 plays an important role in the progression of OTSCC via activation of the Wnt/β-catenin signaling pathway.
Literature
1.
Cooper JS, Porter K, Mallin K et al (2009) National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 31:748–758PubMedCrossRef
2.
Chitapanarux I, Lorvidhaya V, Sittitrai P et al (2006) Oral cavity cancers at a young age: analysis of patient, tumor and treatment characteristics in Chiang Mai University Hospital. Oral Oncol 42:83–88PubMedCrossRef
3.
Hiratsuka H, Miyakawa A, Nakamori K, Kido Y, Sunakawa H, Kohama G (1997) Multivariate analysis of occult lymph node metastasis as a prognostic indicator for patients with squamous cell carcinoma of the oral cavity. Cancer 80:351–356PubMedCrossRef
4.
Kowalski LP, Bagietto R, Lara JR, Santos RL, Silva JJ, Magrin J (2000) Prognostic significance of the distribution of neck node metastasis from oral carcinoma. Head Neck 22:207–214PubMedCrossRef
5.
Lo WL, Kao SY, Chi LY, Wong YK, Chang RC (2003) Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg 61:751–758PubMedCrossRef
6.
7.
Cooper DN, Barondes SH (1999) God must love galectins; he made so many of them. Glycobiology 9:979–984PubMedCrossRef
8.
Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17PubMedCrossRef
9.
Krzeslak A, Lipinska A (2004) Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 9:305–328PubMed
10.
Chiu CG, Strugnell SS, Griffith OL et al (2010) Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 176:2067–2081PubMedCrossRef
11.
Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ, Raz A (2009) Regulation of prostate cancer progression by galectin-3. Am J Pathol 174:1515–1523PubMedCrossRef
12.
Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, Yu LG (2009) Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res 69:6799–6806PubMedCrossRef
13.
Hill M, Mazal D, Biron VA et al (2010) A novel clinically relevant animal model for studying galectin-3 and its ligands during colon carcinogenesis. J Histochem Cytochem 58:553–565PubMedCrossRef
14.
Miranda FA, Hassumi MK, Guimaraes MC et al (2009) Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis. J Histochem Cytochem 57:665–673PubMedCrossRef
15.
Honjo Y, Inohara H, Akahani S et al (2000) Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 6:4635–4640PubMed
16.
Alves PM, Godoy GP, Gomes DQ et al (2011) Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathol Res Pract 207:236–240PubMedCrossRef
17.
Matarrese P, Fusco O, Tinari N et al (2000) Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85:545–554PubMedCrossRef
18.
Giannopoulou M, Dai C, Tan X, Wen X, Michalopoulos GK, Liu Y (2008) Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling. Am J Pathol 173:30–41PubMedCrossRef
19.
Kliment CR, Englert JM, Gochuico BR, Yu G, Kaminski N, Rosas I, Oury TD (2009) Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J Biol Chem 284:3537–3545PubMedCrossRef
20.
Duan L, Yao J, Wu X, Fan M (2006) Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells. Biol Cell 98:479–490PubMedCrossRef
21.
Fracalossi AC, Silva MS, Oshima CT, Ribeiro DA (2010) Wnt/beta-catenin signalling pathway following rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. Exp Mol Pathol 88:176–183PubMedCrossRef
22.
Lo ML (2001) A possible role for the WNT-1 pathway in oral carcinogenesis. Crit Rev Oral Biol Med 12:152–165CrossRef
23.
Moon RT, Bowerman B, Boutros M, Perrimon N (2002) The promise and perils of Wnt signaling through beta-catenin. Science 296:1644–1646PubMedCrossRef
24.
Yan D, Avtanski D, Saxena NK, Sharma D (2012) Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires beta-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem 287:8598–8612PubMedCrossRef
25.
Howard S, Deroo T, Fujita Y, Itasaki N (2011) A positive role of cadherin in Wnt/beta-catenin signalling during epithelial-mesenchymal transition. PLoS One 6:e23899PubMedCrossRef
26.
Kawano Y, Kypta R (2003) Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627–2634PubMedCrossRef
27.
Kocemba KA, Groen RW, van Andel H, Kersten MJ, Mahtouk K, Spaargaren M, Pals ST (2012) Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. PLoS One 7:e30359PubMedCrossRef
28.
Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5:29–41PubMedCrossRef
29.
Saussez S, Lorfevre F, Lequeux T et al (2008) The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol 44:86–93PubMedCrossRef
30.
Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A (2004) Galectin-3, a novel binding partner of beta-catenin. Cancer Res 64:6363–6367PubMedCrossRef
31.
Weinberger PM, Adam BL, Gourin CG et al (2007) Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 133:503–510PubMedCrossRef
32.
Song S, Mazurek N, Liu C et al (2009) Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 69:1343–1349PubMedCrossRef
33.
Staal FJ, Sen JM (2008) The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis. Eur J Immunol 38:1788–1794PubMedCrossRef
34.
Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810PubMedCrossRef
35.
Gan XQ, Wang JY, Xi Y, Wu ZL, Li YP, Li L (2008) Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction. J Cell Biol 180:1087–1100PubMedCrossRef
36.
Hu MC, Rosenblum ND (2005) Smad1, beta-catenin and Tcf4 associate in a molecular complex with the Myc promoter in dysplastic renal tissue and cooperate to control Myc transcription. Development 132:215–225PubMedCrossRef
37.
Udhayakumar G, Jayanthi V, Devaraj N, Devaraj H (2007) Interaction of MUC1 with beta-catenin modulates the Wnt target gene cyclinD1 in H. pylori-induced gastric cancer. Mol Carcinog 46:807–817PubMedCrossRef
38.
Rahmani M, Carthy JM, McManus BM (2012) Mapping of the Wnt/beta-catenin/TCF response elements in the human versican promoter. Methods Mol Biol 836:35–52PubMedCrossRef
39.
Zeilstra J, Joosten SP, Wensveen FM et al (2011) WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer. Biochem Biophys Res Commun 406:1–6PubMedCrossRef
40.
Sancho R, Nateri AS, de Vinuesa AG, Aguilera C, Nye E, Spencer-Dene B, Behrens A (2009) JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J 28:1843–1854PubMedCrossRef
41.
Saadeddin A, Babaei-Jadidi R, Spencer-Dene B, Nateri AS (2009) The links between transcription, beta-catenin/JNK signaling, and carcinogenesis. Mol Cancer Res 7:1189–1196PubMedCrossRef
42.
Giles RH, van Es JH, Clevers H (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653:1–24PubMed
43.
Levy R, Biran A, Poirier F, Raz A, Kloog Y (2011) Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNA. PLoS One 6:e27490PubMedCrossRef
44.
Elad-Sfadia G, Haklai R, Balan E, Kloog Y (2004) Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 279:34922–34930PubMedCrossRef
Metadata
Title
Galectin-3 Accelerates the Progression of Oral Tongue Squamous Cell Carcinoma via a Wnt/β-catenin-Dependent Pathway
Authors
Li-Ping Wang
Shu-Wei Chen
Shi-Min Zhuang
Huan Li
Ming Song
Publication date
01-07-2013
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2013
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-013-9603-7

Other articles of this Issue 3/2013

Pathology & Oncology Research 3/2013 Go to the issue

Research

Selective Ductectomy for the Diagnosis and Treatment of Intraductal Papillary Lesions Presenting with Single Duct Discharge

Research

Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma

Research

Treatment Response to Preoperative Anthracycline-Based Chemotherapy in Locally Advanced Breast Cancer: The Relevance of Proliferation and Apoptosis Rates

Research

Measurement of HER2 in Saliva of Women in Risk of Breast Cancer

Review

Multicentric Castleman’s Disease: A Challenging Diagnosis

Research

High-Risk and Low-Risk Human Papillomavirus in Esophageal Squamous Cell Carcinoma at Mazandaran, Northern Iran

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits